The biotechnology company Galapagos has raised 300 USD in fresh money from American investors, via the issuing of new shares, it said Thursday.
The Mechelen company issued 2,575,107 new shares, at the price of 116.50 dollars per share.
The Bel 20 company announced Wednesday that its Filgotinib, a drug for rheumatism, has performed well in the phase III study, which facilitates a future commercialization.
Michel Deurinck, born in Brussels in 1950, started his career in the Belgian civil service, dedicating over 30 years to public service. Upon retirement, he pursued his passion for journalism. Transitioning into this new field, he quickly gained recognition for his insightful reporting on politics and culture. Deurinck's balanced and thoughtful approach to journalism has made him a respected figure in Belgian media.
